1. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Issue 3 (March 2018) Authors: McQuade, Jennifer L; Daniel, Carrie R; Hess, Kenneth R; Mak, Carmen; Wang, Daniel Y; Rai, Rajat R; Park, John J; Haydu, Lauren E; Spencer, Christine; Wongchenko, Matthew; Lane, Stephen; Lee, Dung-Yang; Kaper, Mathilde; McKean, Meredith; Beckermann, Kathryn E; Rubinstein, Samuel M; Rooney, Isabell... Journal: Lancet oncology Issue: Volume 19:Issue 3(2018) Page Start: 310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer: Results From a Safety Lead-in Study. Issue 9 (1st November 2009) Authors: Vergote, Ignace; Amant, Frederic; Oskay-Öezcelik, Gülten; Musib, Luna; Michel, Anne-Laure; Darstein, Christelle; Kania, Marek; Bauknecht, Thomas; Sehouli, Jalid Journal: International journal of gynecological cancer Issue: Volume 19:Issue 9(2009) Page Start: 1505 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics. Issue 2 (21st July 2020) Authors: Cheeti, Sravanthi; Deng, Yuzhong; Chang, Ilsung; Georgescu, Isabela; Templeton, Ian; Choong, Nicholas; Cheung, Kit Wun Kathy; Girish, Sandhya; Musib, Luna Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 2(2021) Page Start: 144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effects of enzastaurin and its metabolites on the QT interval in cancer patients. (17th August 2015) Authors: Welch, Pamela A.; Ng, Wee Teck; Darstein, Christelle L.; Musib, Luna; Lesimple, Thierry Journal: Journal of clinical pharmacology Issue: Volume 56:Number 1(2016) Page Start: 101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer. (6th March 2019) Authors: Zhu, Rui; Poland, Bill; Wada, Russ; Liu, Qi; Musib, Luna; Maslyar, Daniel; Cho, Eunpi; Yu, Wei; Ma, Han; Jin, Jin Yan; Budha, Nageshwar Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 8:Number 4(2019) Page Start: 240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. MEK inhibitors beyond monotherapy: current and future development. (August 2015) Authors: E Templeton, Ian; Musib, Luna Journal: Current opinion in pharmacology Issue: Volume 23(2015) Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function. (23rd December 2021) Authors: Sane, Rucha; Malhi, Vikram; Sutaria, Dhruvitkumar S; Cho, Eunpi; Twomey, Patrick; Craggs, Christopher; Wang, Jianshuang; Harris, Adam; Musib, Luna Journal: Journal of clinical pharmacology Issue: Volume 62:Number 2(2022) Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Time to Rethink the Current Paradigm for Assessing Kidney Function in Drug Development and Beyond. Issue 5 (18th December 2021) Authors: Sharma, Ashish; Sahasrabudhe, Vaishali; Musib, Luna; Zhang, Steven; Younis, Islam; Kanodia, Jitendra Journal: Clinical pharmacology & therapeutics Issue: Volume 112:Issue 5(2022) Page Start: 946 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗